Literature DB >> 18521103

Prostate cancer chemotherapy in the era of targeted therapy.

A Michael1, K Syrigos, H Pandha.   

Abstract

Prostate cancer is the most common cancer in men accounting for around 24% of all male cancers in United Kingdom. The role of chemotherapy in the neoadjuvant and adjuvant setting is still unclear despite considerable progress in this area. Chemotherapy for advanced prostate cancer has become the standard of care, however options of treatment following taxotere failure are still limited. This review summarizes recent advances in chemotherapy treatment options for early as well as advanced prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18521103     DOI： 10.1038/pcan.2008.32

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN： 1365-7852            Impact factor:   5.554


  8 in total

1.  Racial variation in the cost-effectiveness of chemotherapy for prostate cancer.

Authors:  Michael Grabner; Eberechukwu Onukwugha; Rahul Jain; C Daniel Mullins
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

2.  FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis.

Authors:  Chen Huang; Jiawei Du; Keping Xie
Journal:  Biochim Biophys Acta       Date:  2014-01-11

3.  Design of curcumin loaded cellulose nanoparticles for prostate cancer.

Authors:  Murali Mohan Yallapu; Mitch Ray Dobberpuhl; Diane Michele Maher; Meena Jaggi; Subhash Chand Chauhan
Journal:  Curr Drug Metab       Date:  2012-01       Impact factor: 3.731

4.  Formulation and evaluation of PLGA nanoparticles loaded capecitabine for prostate cancer.

Authors:  Shu-Ben Sun; Ping Liu; Fa-Ming Shao; Qi-Long Miao
Journal:  Int J Clin Exp Med       Date:  2015-10-15

5.  A biocompatible in vivo ligation reaction and its application for noninvasive bioluminescent imaging of protease activity in living mice.

Authors:  Aurélien Godinat; Hyo Min Park; Stephen C Miller; Ke Cheng; Douglas Hanahan; Laura E Sanman; Matthew Bogyo; Allen Yu; Gennady F Nikitin; Andreas Stahl; Elena A Dubikovskaya
Journal:  ACS Chem Biol       Date:  2013-03-29       Impact factor: 5.100

6.  Preparation and characterization of self-assembled nanoparticles based on low-molecular-weight heparin and stearylamine conjugates for controlled delivery of docetaxel.

Authors:  Dong-Hwan Kim; Ubonvan Termsarasab; Hyun-Jong Cho; In-Soo Yoon; Jae-Young Lee; Hyun Tae Moon; Dae-Duk Kim
Journal:  Int J Nanomedicine       Date:  2014-12-08

7.  Pluronic P105/F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation.

Authors:  Liangcen Chen; Xianyi Sha; Xinyi Jiang; Yanzuo Chen; Qiuyue Ren; Xiaoling Fang
Journal:  Int J Nanomedicine       Date:  2013-01-03

8.  Luteolin attenuates Wnt signaling via upregulation of FZD6 to suppress prostate cancer stemness revealed by comparative proteomics.

Authors:  Kun Han; Tingyuan Lang; Zhiqi Zhang; Yi Zhang; Yongning Sun; Zan Shen; Roger W Beuerman; Lei Zhou; Daliu Min
Journal:  Sci Rep       Date:  2018-06-04       Impact factor: 4.379
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.